ClinicalTrials.gg
RecruitingNCT06991049RBESUpdated Oct 30, 2025

Early Versus Late Endoscopic Stenting for Refractory Benign Esophageal Strictures

An interventional study of Fully covered self-expandable metal esophageal stent in Refractory Benign Esophageal Strictures, sponsored by Medical College of Wisconsin. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-30.

Sponsored by Medical College of Wisconsin · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 116 studies in Constriction, Pathologic with a site in United States — 14 open to participants now, 18 under way, 2 of them phase 3. Constriction, Pathologic · United States.

Planned enrollment
58th of 82
20 · median 40
Started
2025
with 4 others
No phase
53 of 116
5 open now
Primary completion
2027-03
later than 7 of 17 live
Registered
110th of 116
by date

Among the 116 studies in Constriction, Pathologic with a site in United States, this one is the 58th largest by planned enrollment of the 82 interventional ones that give a count, is one of 5 that started in 2025, is one of 53 with no phase, reaches primary completion later than 7 of the 17 other live ones, and was the 110th registered.

Constriction, Pathologic

457 studies on the registry are indexed under Constriction, Pathologic; 110 are open to participants now.

Browse Constriction, Pathologic studies →

Open to participants now

14 of the 116 studies in Constriction, Pathologic with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 67 Constriction, Pathologic studies recruiting now, 34 (51%) set no upper age limit and 14 (21%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 116 studies in Constriction, Pathologic with a site in United States, or all of them as a file.
02

Study summary

This project is being done to compare two current treatment clinical options for management of RBES: 1) Frequent dilations followed by temporary esophageal stent placement if dilations fail, or 2) Early stent placement followed by dilations

Read the detailed description

This study aims to explore the safety and effectiveness of two clinical treatment approaches used to manage RBES patients-Temporary early-stent placement versus late stenting.

For normal swallowing, the esophagus (food pipe) lumen should be equal to or more than 14 mm in diameter. In those with stricture (narrowing) of the esophagus from benign causes, initial endoscopic management is serial sessions of dilation (stretching) to achieve and maintain a diameter of ≥14mm. Many strictures may not respond to this approach (refractory). Esophageal stents (18 mm - 23 mm diameter) temporarily placed for 2 weeks using an endoscope are also used dilate and remold the stricture. While in place, patients can swallow. This can save the patient from undergoing repeated dilations. Stents can be placed either late in the process of management after several traditional dilations have failed or early in the management to rapidly achieve a diameter of ≥14 mm and then continuing traditional dilations.

Although either of above two approaches can be used for the clinical management of RBES, in this study the investigators plan to randomly assign patients to start with one of the two approaches and compare outcomes.

03

Conditions studied

  • Refractory Benign Esophageal Strictures

Keywords

  • Refractory Benign Esophageal Strictures
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to give informed and written consent.
  • Able to keep follow up appointments as per protocol (minimum 2 years).
  • proven benign esophageal stricture.
  • Dysphagia (grade 2 and above).
  • Fit to undergo upper GI endoscopy.
  • Documented esophageal stricture with a luminal diameter \<14 mm at index endoscopy.

Exclusion criteria

Exclusion Criteria:

  • Minimal dysphagia (grade 0-1)
  • Neuromuscular dysphagia (such as achalasia, oro-pharyngeal dysphagia post-stroke, crico-pharyngeal bar, Zenker diverticulum etc.)
  • Pregnant or planning to be pregnant during the study period.
  • Malignant or indeterminate esophageal stricture.
  • Actively receiving radiation therapy.
  • Persistent associated active esophagitis that has not yet healed.
  • Esophageal strictures associated with fistula/leaks/current or prior perforation.
  • Eosinophilic esophagitis.
  • Associated esophageal varices.
  • No other limiting .
  • Patients in whom placing esophageal stents is not possible/ (such as high cervical esophageal strictures, active bleeding, metal allergy, tortuous esophagus, pseudodiverticulum with stricture).
  • Previous esophageal stent tried over 2 months ago
  • Significant comorbidities making patient high risk for upper GI endoscopy.
  • Unable to give .
  • Cannot keep follow up appointments as per protocol.
  • Procedures and stents not covered by patient's insurance.
  • Patients who, after comprehensive discussion and explanation of both the early-stent and late-stent approaches, choose to proceed with a specific approach and decline participation in randomization.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    Late-stent approach

    Repeated dilations at weekly intervals, and based on the response, the intervals between dilations are adjusted, and if still no response, place a removable FCSEMS (18 mm diameter). The stent will be removed in 2 weeks followed again by weekly dilations till less than one dilation is needed every 3 months to maintain a luminal diameter of 14 mm or more.

    Device: Fully covered self-expandable metal esophageal stent

  • Active comparator
    Early-stent approach

    Removable FCSEMS (18 mm diameter) placed on index endoscopy and removed after 2 weeks followed by weekly dilations till less than one dilation is needed every 3 months to maintain a luminal diameter of 14 mm or more.

    Device: Fully covered self-expandable metal esophageal stent

Interventions

  • DeviceFully covered self-expandable metal esophageal stent

    Esophageal stent placement for patients with benign esophageal strictures not responding to endoscopic dilations.

06

What researchers measure

Primary outcomes

  1. Time to achieve esophageal luminal diameter to ≥14 mm

    The duration required to achieve and maintain an esophageal diameter of ≥14 mm using the two techniques.

    Time frame: From enrollment to follow up, up to 2 years

Secondary outcomes

  1. Adverse event rate

    Time frame: From enrollment to follow up, up to 2 years

  2. Recurrence rate of esophageal stricture

    Time frame: From enrollment to follow up, up to 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Mar 2027, 17 months after the start.

Of 90 non-industry interventional studies with no phase under Constriction, Pathologic, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 49. This study's planned 17 months is below that.

Counting every sponsor, half of 133 studies reached it within 36 months; a quarter within 18 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2025
First posted
May 25, 2025
StartActual
Oct 14, 2025
Primary completionEst.
Mar 21, 2027
CompletionEst.
Jul 2027
Last update
Oct 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06991049
Responsible party
Kulwinder Dua, MD (Professor of Medicine, Medical College of Wisconsin) — Principal investigator
First posted
May 25, 2025
Start date
Oct 14, 2025
Primary completion
Mar 21, 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Oct 30, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion